Interleukin‐17, Interleukin‐18, T Regulatory Cells, and T‐Helper 17 (Th17) Cells Play a Role in Heart Failure: A Systematic Review and Meta‐Analysis
Cardiology Research and Practice · 2026-01 · 2026 (1)
DOI: 10.1155/crp/5979003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiology Research and Practice, online erschienen am 24.05.2026. Verfasst von Sohat Sharma und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of British Columbia, Vancouver, British Columbia, Canada, ubc.ca. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
The objective of this study was to assess whether interleukin‐17 or 18 (IL‐17 or IL‐18), regulatory T cells (Tregs), and T helper17 (Th17) serum concentrations were different in chronic heart failure not associated with myocarditis compared to healthy individuals.
Methods
We searched MEDLINE and Embase for studies with data on IL‐17 or IL‐18 serum concentrations in patients with chronic heart failure. Forest plots were used to quantify results and depict the standard difference of means, 95% confidence interval (CI), and p value. Continuous outcomes were assessed as weighted mean differences (WMD) with their 95% CI.
Results
IL‐17 was significantly ( p < 0.05) higher in patients with heart failure. The combined effect size under the random effects model (MD = 40.00 pg/mL, 95% CI [6.04, 73.96], p < 0.001) showed a significant overall increase in IL‐17 serum levels in heart failure. Th17 was significantly ( p < 0.05) higher in patients with heart failure, and Tregs are significantly lower compared to persons without heart failure. The random effects model indicates an MD of 1.59 pg/mL (95% CI [0.88, 2.30]), highlighting significant elevation of TH17 levels in heart failure. For Tregs, the random effects model presented an MD of −2.96 pg/mL (95% CI [−4.52, −1.40]), both indicating a significant decrease in Treg levels in HF. Additionally, serum IL‐17 concentrations correlated with the severity of the reduction in LV ejection fraction. For IL‐18, all (five) studies reported a statistically significant increase in IL‐18 levels in HF. The pooled mean difference was 251.59 pg/mL (95% CI: 177.24–325.93 pg/mL) with a random effects model.
Conclusion
Serum IL‐17, IL‐18 Th17, and Treg count have utility for risk stratification for patients with heart failure, as biomarkers for heart failure severity and potential target pathways for treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of British Columbia, Vancouver, British Columbia, Canada, ubc.ca.
- Department of Medicine, Division of Cardiology, Vancouver, British Columbia, Canada.
ORCID-Profile: Cameron J Leong, Simon W Rabkin
Zitieren
APA
Sharma, S., Seth, J., Leong, C. J., & Rabkin, S. W. (2026). Interleukin‐17, Interleukin‐18, T Regulatory Cells, and T‐Helper 17 (Th17) Cells Play a Role in Heart Failure: A Systematic Review and Meta‐Analysis. Cardiology Research and Practice, 2026(1). https://doi.org/10.1155/crp/5979003
Vancouver
Sharma S, Seth J, Leong CJ, Rabkin SW. Interleukin‐17, Interleukin‐18, T Regulatory Cells, and T‐Helper 17 (Th17) Cells Play a Role in Heart Failure: A Systematic Review and Meta‐Analysis. Cardiology Research and Practice. 2026;2026(1). doi:10.1155/crp/5979003
BibTeX
@article{Sharma2026,
author = {Sharma, Sohat and Seth, Jayant and Leong, Cameron J and Rabkin, Simon W},
title = {Interleukin‐17, Interleukin‐18, T Regulatory Cells, and T‐Helper 17 (Th17) Cells Play a Role in Heart Failure: A Systematic Review and Meta‐Analysis},
journal = {Cardiology Research and Practice},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crp/5979003}
}
EUVIMED